Form 10 Explorer
10-Q
Quarterly Report
AIM IMMUNOTECH INC.

AIM

NYSEAMER

CIK: 946644

File #: 001-27072

Period End: Mar 31, 2026

Fiscal Year: 2026

View on EDGAR
Balance Sheet
40 line items · 2 periods
XBRL
ItemMar 31, 2026Dec 31, 2025
ASSETS
Current assets:
Cash and Cash Equivalents
5,816,0002,985,000
Marketable securities
63,00062,000
Fair Value, Recurring
63,00062,000
Fair Value, Inputs, Level 1 - Fair Value, Recurring
63,00062,000
Accounts Receivable
7,000
Other Non-Operating Current Assets
335,000241,000
Total current assets
6,214,0003,295,000
Property, Plant and Equipment
62,00071,000
Operating Lease Right-of-Use Asset
320,000378,000
Intangible Assets
1,662,0001,661,000
Patents
1,603,0001,599,000
Trademarks
59,00062,000
Other Non-Operating Non-Current Assets
327,000377,000
Total assets
8,585,0005,782,000
LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT)
Current liabilities:
Accounts Payable
1,215,0001,630,000
Other Current Liabilities
671,000795,000
Operating Lease Liability, Current
255,000250,000
Short-Term Debt
4,004,0003,549,000
Total current liabilities
6,145,0006,224,000
Long-term liabilities:
Operating Lease Liability, Non-Current
105,000170,000
Long-Term Debt
210,000927,000
Other Non-Operating Non-Current Liabilities
8,244,000
Fair Value, Recurring
8,244,000
Total liabilities
6,460,00015,565,000
Stockholders’ equity (deficit):
Total Stockholders' Equity
8,0003,000
Total Stockholders' Equity
445,926,000431,000,000
Total Stockholders' Equity
(443,809,000)(440,786,000)
Total stockholders’ equity (deficit)
2,125,000(9,783,000)
Series G Preferred Stock - Preferred Stock
678,000
Common Stock
8,0003,000
Additional Paid-in Capital
445,926,000431,000,000
Retained Earnings
(443,809,000)(440,786,000)
Minimum
6,000,000
Total liabilities and stockholders’ equity (deficit)
8,585,0005,782,000
AIM IMMUNOTECH INC. (AIM) — 10-Q Filing | Form 10 Explorer